ClinicalTrials.gg
TerminatedNCT00779220Updated Mar 25, 2015

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid Arthritis

A Phase 2 interventional study of placebo and methotrexate in Rheumatoid Arthritis, sponsored by Chugai Pharmaceutical. Terminated at 7 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-03-25.

Sponsored by Chugai Pharmaceutical (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Hoffmann-La Roche.

Enrollment
65th of 141
152 · median 132
Started
2008
with 10 others
Phase 2
20 of 219
2 open now
Registered
53rd of 219
by date

Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 65th largest by enrollment of the 141 interventional ones that give a count, is one of 11 that started in 2008, is one of 20 in phase 2, and was the 53rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety and PK/PD of ocrelizumab at each dose in combination with methotrexate(MTX)in patients with active rheumatoid arthritis (RA). The data from this study will also be compared with those from a clinical study of ocrelizumab in patients with active RA that was conducted in the U.S.

Read the detailed description

This study will evaluate the efficacy, safety and PK/PD of ocrelizumab at each dose in combination with MTX in patients with active RA. The data from this study will also be compared with those from a clinical study of ocrelizumab in patients with active RA that was conducted in the U.S.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of RA for ≧6 months according to the revised 1987 ACR criteria for the classification of RA.
  • Adult patients, ≧20 years of age.
  • Receiving methotrexate at a dose of 6 to 8mg/week(oral)for ≧12 weeks, with a stable dose for the last 4 weeks before treatment.
  • Positive serum RF.

Exclusion criteria

Exclusion Criteria:

  • Rheumatic disease other than RA, or Significant systemic involvement secondary to RA (including but not limited to vasculitis, pulmonary fibrosis, or Felty's syndrome).Patients with secondary Sjögren's syndrome or secondary limited cutaneous vasculitis with RA are eligible.
  • Functional Class Ⅳ as defined by the ACR Classification of Functional Status in RA.
  • History of or current inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or other overlap syndrome).
  • Any surgical procedure (except for minor surgeries requiring local or no anaesthesia and without any complications or sequelae) within 12 weeks prior to or planned within 24 weeks after baseline.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
152 participants (actual)

Study arms

  • Placebo comparator
    1

    Drug: placebo · Drug: methotrexate

  • Experimental
    2

    Drug: methotrexate · Drug: ocrelizumabu 50mg

  • Experimental
    3

    Drug: methotrexate · Drug: ocrelizumabu 200mg

  • Experimental
    4:

    Drug: methotrexate · Drug: ocrelizumab 500mg

Interventions

  • Drugplacebo

    Intravenous repeating dose

  • Oral repeating dose

  • Drugocrelizumabu 50mg

    Intravenous repeating dose (50mg)

  • Drugocrelizumabu 200mg

    Intravenous repeating dose (200mg)

  • Intravenous repeating dose (500mg)

06

What researchers measure

Primary outcomes

  1. Percentage of patients with ACR20 response.

    Time frame: week 24

Secondary outcomes

  1. Percentage of patients with ACR20, 50, and 70 response, and the components of this outcome.

    Time frame: very 4 Weeks, from Week 4 to Week 24

  2. EULAR response rate.

    Time frame: Every 4 Weeks, from Week 4 to Week 24

  3. DAS 28, HAQ-DI score.

    Time frame: Every 4 Weeks, from Week 4 to Week 24

  4. FACIT Fatigue Scale score

    Time frame: Weeks 4,12,and 24

  5. Weeks 4,12,and 24

    Time frame: Length of study

  6. Incidence of human anti-human(ocrelizumab) antibodies (HAHA)

    Time frame: Length of study

  7. Pharmacokinetics and Pharmacodynamics of ocrelizumab.

    Time frame: Length of study

07

Study locations

7 sites
  • Chubu region
    Chubu, Japan
  • Chugoku region
    Chugoku, Japan
  • Hokkaido Region
    Hokkaido, Japan
  • Kanto Region
    Kanto, Japan
  • Kinki Region
    Kinki, Japan
  • Kyusyu region
    Kyusyu, Japan
  • Sikoku region
    Sikoku, Japan
08

References and documents

Publications

  • Harigai M, Tanaka Y, Maisawa S; JA21963 Study Group. Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo-controlled double-blind parallel-group study. J Rheumatol. 2012 Mar;39(3):486-95. doi: 10.3899/jrheum.110994. Epub 2012 Jan 15. PubMed 22247354 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Feb 2010 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2008
First posted
Oct 24, 2008
Start
Oct 2008
Primary completionActual
Feb 2010
CompletionActual
Mar 2015
Last update
Mar 25, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00779220
Responsible party
Sponsor
First posted
Oct 24, 2008
Start date
Oct 2008
Primary completion
Feb 2010
Completion
Mar 2015
Last update
Mar 25, 2015

Study contacts

Naritoshi Mochidome
study chair · Chugai Pharmaceutical

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion